GENELUX Corp (GNLX) shareholders
Close on Nov 17, 2026Market cap $90.49MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 4,223,277 | 9.99% | 13G (passive) | Sep 30, 2025 |
| Aladar Szalay | 2,834,465 | 6.20% | 13G (passive) amendment | Sep 30, 2026 |
| Highbridge Capital Management, LLC | 2,500,000 | 6.80% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GNLX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Woodward Diversified Capital, LLC | 2,262,108 | 5.00% | $6.81M | +144,925 | 3.00% |
| Vanguard Capital Management LLC | 1,677,724 | 3.71% | $5.05M | −17,756 | 0.00% |
| Bleichroeder LP | 1,380,666 | 3.05% | $4.16M | – | 0.74% |
| BlackRock, Inc. | 439,602 | 0.97% | $1.32M | +33,730 | 0.00% |
| Geode Capital Management, LLC | 439,213 | 0.97% | $1.32M | −14,548 | 0.00% |
| CM Management, LLC | 400,000 | 0.88% | $1.20M | +150,000 | 0.80% |
| Bank Of America Corp /De/ | 328,803 | 0.73% | $989.70K | +4,938 | 0.00% |
| Vanguard Fiduciary Trust Co | 236,344 | 0.52% | $711.40K | −15,266 | 0.00% |
| Flputnam Investment Management Co | 231,405 | 0.51% | $696.53K | −49,499 | 0.01% |
| Global Retirement Partners, LLC | 227,854 | 0.50% | $685.84K | New | 0.01% |
| LPL Financial LLC | 157,857 | 0.35% | $475.15K | +18,816 | 0.00% |
| State Street Corp | 145,850 | 0.32% | $439.01K | – | 0.00% |
| Provident Wealth Management, LLC | 144,908 | 0.32% | $436.17K | −10,762 | 0.11% |
| LifeSteps Financial, Inc. | 121,965 | 0.27% | $367.12K | +3,103 | 0.17% |
| Osaic Holdings, Inc. | 121,958 | 0.27% | $367.09K | +2,950 | 0.00% |
| Renaissance Technologies LLC | 105,229 | 0.23% | $316.74K | +93,029 | 0.00% |
| Northern Trust Corp | 89,279 | 0.20% | $268.73K | −75,177 | 0.00% |
| Citadel Advisors LLC | 85,481 | 0.19% | $257.30K | New | 0.00% |
| Morgan Stanley | 83,543 | 0.18% | $251.46K | −4,505 | 0.00% |
| SteelPeak Wealth, LLC | 75,895 | 0.17% | $228.44K | +15,000 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 10M | 21.7% | 11 / 19 | 15 / 10 | 1M | 1M |
| Q1 2026 | 71 | 9M | 20.6% | 12 / 16 | 14 / 17 | 3M | 1M |
| Q4 2025 | 78 | 9M | 20.2% | 22 / 20 | 12 / 1 | 2M | 0M |
| Q3 2025 | 57 | 7M | 16.5% | 6 / 21 | 5 / 10 | 1M | 1M |
| Q2 2025 | 61 | 7M | 16.3% | 7 / 19 | 11 / 21 | 1M | 1M |
| Q1 2025 | 75 | 7M | 16.1% | 26 / 21 | 12 / 8 | 3M | 0M |
| Q4 2024 | 58 | 5M | 10.8% | 9 / 11 | 20 / 7 | 1M | 1M |
| Q3 2024 | 57 | 5M | 11.6% | 5 / 17 | 17 / 20 | 1M | 2M |
| Q2 2024 | 73 | 7M | 15.7% | 26 / 15 | 20 / 20 | 3M | 2M |
| Q1 2024 | 67 | 6M | 13.6% | 17 / 23 | 14 / 9 | 1M | 1M |
| Q4 2023 | 61 | 6M | 13.0% | 13 / 27 | 9 / 8 | 2M | 0M |
| Q3 2023 | 56 | 4M | 9.4% | 25 / 26 | 1 / 4 | 4M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
18 funds held GNLX in Q1 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GNLX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,193,626 | 2.64% | $3.59M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 467,369 | 1.03% | $1.41M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 211,075 | 0.47% | $643.78K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 138,046 | 0.31% | $415.52K | 0.03% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 62,137 | 0.14% | $189.52K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 58,298 | 0.13% | $177.81K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 34,323 | 0.08% | $103.31K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 26,033 | 0.06% | $79.40K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 25,000 | 0.06% | $73.50K | 0.00% | Jul 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 16,729 | 0.04% | $50.35K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 9,299 | 0.02% | $27.99K | 0.01% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 4,629 | 0.01% | $13.61K | 0.00% | Jul 31, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 228 | 0.00% | $670 | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -300 | -0.00% | -$903 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yong Yu | Chief Scientific Officer | 258,020 | 0.57% | Nov 5, 2026 |
| Thomas Zindrick | President and CEO | 1,423,338 | 3.15% | Nov 5, 2026 |
| Joseph Cappello | Chief Technical Officer | 317,812 | 0.70% | Nov 5, 2026 |
| Eric Groen | General Counsel | 233,957 | 0.52% | Jun 18, 2026 |
| Matthew Pulisic | Chief Financial Officer | 278,906 | 0.62% | Jun 18, 2026 |
| Ralph Smalling | Head of Regulatory | 67,611 | 0.15% | Jun 4, 2026 |
| Jason Litten | Chief Medical Officer | – | – | Jan 7, 2026 |
| Sean Ryder | General Counsel | 47,621 | 0.11% | May 13, 2025 |
| Lourie S. Zak | Chief Financial Officer | 82,452 | 0.18% | Dec 20, 2024 |
| John W. Smither | Director | 91,403 | 0.20% | Jul 2, 2026 |
| Mary Mirabelli | Director | 102,693 | 0.23% | Jun 18, 2026 |
| John Thomas | Director | 501,193 | 1.11% | Jun 18, 2026 |
| James L. Tyree | Director | 96,483 | 0.21% | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph Cappello Chief Technical Officer | Nov 3, 2026 | Sale | −668 | $2.04 | $1.36K | 317,812 |
| Thomas Zindrick President and CEO | Nov 3, 2026 | Sale | −3,089 | $2.05 | $6.32K | 1,223,338 |
| Yong Yu Chief Scientific Officer | Nov 3, 2026 | Sale | −668 | $2.01 | $1.34K | 258,020 |
| Yong Yu Chief Scientific Officer | Aug 31, 2026 | Sale | −9,683 | $2.75 | $26.63K | 258,688 |
| Joseph Cappello Chief Technical Officer | Aug 31, 2026 | Sale | −10,257 | $2.74 | $28.10K | 318,480 |
| Thomas Zindrick President and CEO | Aug 31, 2026 | Sale | −34,463 | $2.67 | $92.02K | 1,226,427 |
| Yong Yu Chief Scientific Officer | Aug 4, 2026 | Sale | −653 | $2.94 | $1.92K | 268,371 |
| Joseph Cappello Chief Technical Officer | Aug 4, 2026 | Sale | −653 | $2.95 | $1.93K | 328,737 |
| Thomas Zindrick President and CEO | Aug 4, 2026 | Sale | −3,023 | $2.95 | $8.92K | 1,260,890 |
| John W. Smither Director | Jul 1, 2026 | Sale | −12,000 | $2.91 | $34.92K | 91,403 |
| Matthew Pulisic Chief Financial Officer | Jun 16, 2026 | Award | +278,906 | – | – | 278,906 |
| Thomas Zindrick President and CEO | Jun 16, 2026 | Award | +730,601 | – | – | 1,263,913 |
| Joseph Cappello Chief Technical Officer | Jun 16, 2026 | Award | +174,841 | – | – | 329,390 |
| James L. Tyree Director | Jun 16, 2026 | Award | +28,409 | – | – | 96,483 |
| Yong Yu Chief Scientific Officer | Jun 16, 2026 | Award | +119,318 | – | – | 269,024 |
| John Thomas Director | Jun 16, 2026 | Award | +28,409 | – | – | 501,193 |
| Eric Groen General Counsel | Jun 16, 2026 | Award | +233,957 | – | – | 233,957 |
| John W. Smither Director | Jun 16, 2026 | Award | +28,409 | – | – | 103,403 |
| Mary Mirabelli Director | Jun 16, 2026 | Award | +28,409 | – | – | 102,693 |
| Ralph Smalling Head of Regulatory | Jun 3, 2026 | Sale | −192 | $2.93 | $563 | 67,611 |
| John Thomas Director | Jun 1, 2026 | Sale(10b5-1 plan) | −10,000 | $2.98 | $29.80K | 472,784 |
| Joseph Cappello Chief Technical Officer | May 11, 2026 | Sale | −605 | $2.97 | $1.80K | 154,549 |
| Thomas Zindrick President and CEO | May 11, 2026 | Sale | −2,798 | $2.94 | $8.23K | 532,051 |
| Yong Yu Chief Scientific Officer | May 11, 2026 | Sale | −605 | $2.97 | $1.80K | 149,706 |
| Ralph Smalling Head of Regulatory | May 11, 2026 | Sale | −270 | $2.98 | $805 | 67,803 |
| Ralph Smalling Head of Regulatory | Mar 25, 2026 | Sale | −240 | $2.51 | $602 | 68,073 |
| Thomas Zindrick President and CEO | Mar 24, 2026 | Sale | −3,582 | $2.42 | $8.67K | 534,849 |
| Joseph Cappello Chief Technical Officer | Mar 24, 2026 | Sale | −906 | $2.42 | $2.19K | 155,154 |
| Yong Yu SVP, Clinical Development | Mar 24, 2026 | Sale | −906 | $2.42 | $2.19K | 144,938 |
| Ralph Smalling Head of Regulatory | Mar 24, 2026 | Sale | −345 | $2.42 | $835 | 68,313 |
| John Thomas Director | Mar 2, 2026 | Sale(10b5-1 plan) | −10,000 | $2.90 | $29.00K | 482,784 |
| Ralph Smalling Head of Regulatory | Dec 5, 2025 | Sale | −165 | $4.69 | $774 | 68,658 |
| John Thomas Director | Dec 1, 2025 | Sale(10b5-1 plan) | −10,000 | $5.00 | $50.00K | 492,784 |
| Thomas Zindrick President and CEO | Nov 17, 2025 | Sale | −4,509 | $5.37 | $24.21K | 538,431 |
| Joseph Cappello Chief Technical Officer | Nov 17, 2025 | Sale | −973 | $5.37 | $5.23K | 156,060 |
| Yong Yu SVP, Clinical Development | Nov 17, 2025 | Sale | −973 | $5.37 | $5.23K | 145,844 |
| Ralph Smalling Head of Regulatory | Nov 17, 2025 | Sale | −343 | $5.37 | $1.84K | 68,823 |
| Ralph Smalling Head of Regulatory | Sep 3, 2025 | Sale | −580 | $3.36 | $1.95K | 69,166 |
| Ralph Smalling Head of Regulatory | Sep 1, 2025 | Award | +10,000 | – | – | 70,990 |
| Ralph Smalling Head of Regulatory | Aug 27, 2025 | Award | +26,230 | – | – | 60,990 |
| Mary Mirabelli Director | Aug 27, 2025 | Award | +22,283 | – | – | 73,284 |
| John W. Smither Director | Aug 27, 2025 | Award | +22,283 | – | – | 74,994 |
| James L. Tyree Director | Aug 27, 2025 | Award | +22,283 | – | – | 68,074 |
| Thomas Zindrick President and CEO | Aug 27, 2025 | Award | +361,200 | – | – | 554,161 |
| Yong Yu SVP, Clinical Development | Aug 27, 2025 | Award | +101,480 | – | – | 150,036 |
| John Thomas Director | Aug 27, 2025 | Award | +22,283 | – | – | 502,784 |
| Joseph Cappello Chief Technical Officer | Aug 27, 2025 | Award | +107,500 | – | – | 159,766 |
| Thomas Zindrick President and CEO | Aug 21, 2025 | Sale | −12,673 | $3.33 | $42.20K | 542,940 |
| Joseph Cappello Chief Technical Officer | Aug 21, 2025 | Sale | −1,463 | $3.36 | $4.92K | 157,033 |
| Joseph Cappello Chief Technical Officer | Aug 21, 2025 | Sale | −1,270 | $3.33 | $4.23K | 158,496 |
| Yong Yu SVP, Clinical Development | Aug 21, 2025 | Sale | −3,219 | $3.36 | $10.82K | 146,817 |
| Ralph Smalling Head of Regulatory | Aug 21, 2025 | Sale | −1,244 | $3.36 | $4.18K | 69,746 |
| John Thomas Director | Jun 6, 2025 | Gift | −25,000 | – | – | 480,501 |
| Yong Yu VP, Clinical Trial Operations | May 12, 2025 | Sale | −5,579 | $2.92 | $16.29K | 47,640 |
| Thomas Zindrick President and CEO, Director | May 12, 2025 | Sale | −10,764 | $2.92 | $31.43K | 191,447 |
| Ralph Smalling Head of Regulatory | May 12, 2025 | Sale | −1,259 | $2.92 | $3.68K | 34,760 |
| Sean Ryder General Counsel | May 12, 2025 | Sale | −4,475 | $2.92 | $13.07K | 47,621 |
| Joseph Cappello VP, Pharmaceutical Development | May 12, 2025 | Sale | −4,737 | $2.92 | $13.83K | 52,266 |
| Joseph Cappello VP, Pharmaceutical Development | Mar 14, 2025 | Award | +13,350 | – | – | 57,003 |
| Yong Yu VP, Clinical Trial Operations | Mar 14, 2025 | Award | +13,350 | – | – | 53,219 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Genelux's stock actually held short. Settlement fails (shares not delivered on time) peaked at 27,279 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John W. Smither Director | Jul 1, 2026 | 12,000 | $34.90K | Jul 1, 2026 | Restricted Stock |
| Johnny Thomas Officer | Jun 1, 2026 | 10,000 | $30.50K | Jun 1, 2026 | Founders Shares |
| Johnny Thomas Officer | Mar 2, 2026 | 10,000 | $29.80K | Mar 2, 2026 | Founders Shares |
| Johnny Thomas Director | Dec 1, 2025 | 10,000 | $55.60K | Dec 1, 2025 | Founders Shares |
| James L. Tyree Director | Dec 30, 2024 | 3,460 | $8.51K | Dec 30, 2024 | Restricted stock vesting under a registered plan |
| James L. Tyree Director | Sep 11, 2024 | 1,730 | $4.34K | Sep 11, 2024 | Restricted Stock Units |
| Szalay 2010 Retained Annuity Trust 10% Stockholder | Sep 6, 2024 | 140,000 | $392.00K | Sep 9, 2024 | Irrevocable Grant |
| Szalay 2010 Retained Annuity Trust 10% Stockholder | Aug 22, 2024 | 400,000 | $872.00K | Aug 23, 2024 | Irrevocable Grant |
| Szalay 2010 Retained Annuity Trust 10% Stockholder | Apr 15, 2024 | 494,744 | $2.10M | Apr 15, 2024 | Irrevocable Grant |
| Szalay 2010 Retained Annuity Trust 10% Stockholder | Apr 11, 2024 | 494,744 | $2.10M | Apr 15, 2024 | Private Placement |
| Yong Yu Officer | Dec 15, 2023 | 32,535 | $428.18K | Dec 15, 2023 | Restricted stock vesting under a registered plan |
| Johnny Thomas Director | Dec 13, 2023 | 9,000 | $120.39K | Dec 13, 2023 | Restricted stock vesting under a registered plan |
| James L. Tyree Officer | Dec 13, 2023 | 9,000 | $118.97K | Dec 13, 2023 | Restricted stock vesting under a registered plan |
| Yong Yu Officer | Dec 7, 2023 | 36,800 | $436.00K | Dec 7, 2023 | Restricted stock vesting under a registered plan |
| Yong Yu Officer | Nov 17, 2023 | 36,800 | $479.14K | Nov 17, 2023 | Restricted stock vesting under a registered plan |
See a number that looks wrong?